

APR 14 2009


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the Application.

LISTING OF CLAIMS:

1-8 (cancelled)

9. (currently amended) The compound according to ~~claim 8~~, of Formula IV.



IV

or a pharmaceutically acceptable salt thereof, wherein

X is selected from -H, -OR⁶, -S(O)₀₋₂R⁶, -N(R⁶)R⁷, -O-N(R⁶)R⁷, -N(R⁶)OR⁶, -N(R⁶)N(R⁶)R⁷, absent, oxo, thiono, and imino, with the proviso that when X is oxo, thiono, or imino, there is only one R¹;

R¹ and R², at each occurrence, are each independently selected from -H, halogen, -CN, -NH₂, -NO₂, -OR⁶, -N(R⁶)R⁷, -S(O)₀₋₂R⁷, -SO₂N(R⁶)R⁷, -CO₂R⁶, -C(O)N(R⁶)R⁷, -N(R⁶)SO₂R⁷, -N(R⁶)C(O)R⁷, -N(R⁶)CO₂R⁷, -C(O)R⁶, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, absent, and optionally substituted lower heterocyclylalkyl;

optionally two of R² together are oxo;

optionally, at least one pair of substituents, selected from two of R¹, two of R², and one each of R¹ and R², together with the corresponding carbon or carbons to which they are attached, form a first ring comprising between three and seven annular atoms, said first ring optionally substituted with between zero and four additional of R¹, each

EX04-019C-US

Page 3 of 14

independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the first ring to which they are attached, form a second ring comprising between three and seven annular atoms, said second ring optionally substituted with between zero and three of R^1 ;

R^3 is selected from -H, optionally substituted lower alkyl, optionally substituted lower arylalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted alkoxy;

optionally R^3 and one of R^2 , together with the atoms to which each is attached, form a third ring comprising between three and seven annular atoms, said third ring optionally substituted with between zero and four additional of R^1 , each independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the third ring to which they are attached, form a fourth ring comprising between three and seven annular atoms, said fourth ring optionally substituted with between zero and three of R^1 ;

optionally R^3 and one of R^1 , together with the atoms to which they are attached and the carbon to which R^2 is attached, form a fifth ring comprising between three and seven annular atoms, said fifth ring optionally substituted with between zero and four additional of R^1 , each independently selected as defined above and optionally, when paired, together with the corresponding atom or atoms of the fifth ring to which they are attached, form a sixth ring comprising between three and seven annular atoms, said sixth ring optionally substituted with between zero and three of R^1 ;

m is zero to four;

each of R^4 is independently selected from -H, halogen, -CN, -NH₂, -NO₂, -OR⁶, -N(R⁶)R⁷, -S(O)₀₋₂R⁷, -SO₂N(R⁶)R⁷, -CO₂R⁶, -C(O)N(R⁶)R⁷, -N(R⁶)SO₂R⁷, -N(R⁶)C(O)R⁷, -N(R⁶)CO₂R⁷, -C(O)R⁶, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

EX04-019C-US

Page 4 of 14

~~each Y is independently either $=C(R^5)$ or $=N$, provided that there are no more than three of $=N$ in the aromatic ring bearing Y;~~

~~each Z is independently either $=C(R^4)$ or $=N$;~~

n is zero to five;

each R^5 is independently selected from -H, halogen, -CN, -NH₂, -NO₂, -OR⁶, -NR⁶R⁷, -S(O)₀₋₂R⁷, -SO₂NR⁶R⁷, -CO₂R⁶, -C(O)NR⁶R⁷, -N(R⁶)SO₂R⁷, -N(R⁶)C(O)R⁷, -N(R⁶)CO₂R⁷, -C(O)R⁶, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

R^6 is -H or R^7 ;

R^7 is selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

R^6 and R^7 , when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P.

10. (withdrawn) The compound according to claim 9, wherein X is selected from -OR⁶,

-SR⁶, and -N(R⁶)R⁷.


11. (withdrawn) The compound according to claim 10, wherein two of R^1 , together with the carbon or carbons to which they are attached, form said second ring.

12. (withdrawn) The compound according to claim 11, wherein said second ring is a six-membered aryl, fused with said first ring, said second ring optionally substituted with between zero and three of R^1 .

13. (withdrawn) The compound according to claim 12, of formula V.


EX04-019C-US

Page 5 of 14



V

14. (withdrawn) The compound according to claim 13, wherein X is -OR⁶.
15. (withdrawn) The compound according to claim 14, wherein R³ is -H.
16. (withdrawn) The compound according to claim 15, wherein X is -OH.
17. (withdrawn) The compound according to claim 16, of formula VI.



VI

18. (withdrawn) The compound according to claim 17, wherein R¹, R⁴, and R⁵ are -H.
- 19-29. (cancelled)
30. (currently amended) A compound according to Table 3:







Table 3

#	Name	Structure
1	N-cyclohexyl-2-pyridin-4-ylquinazolin-4-amine	

EX04-019C-US

Page 6 of 14

Table 3

#	Name	Structure
3	N-cyclopentyl-2-pyridin-4-ylquinazolin-4-amine	
4	N-(cyclohexylmethyl)-2-pyridin-4-ylquinazolin-4-amine	
7	N-[(4-fluorophenyl)methyl]-2-pyridin-4-ylquinazolin-4-amine	
9	N-(2,3-dihydro-1H-inden-1-yl)-2-pyridin-4-ylquinazolin-4-amine	
12	2-pyridin-4-yl-N-[(2R)-1,2,3,4-tetrahydronaphthalen-2-yl]quinazolin-4-amine	
15	2-pyridin-4-yl-N-[(2S)-1,2,3,4-tetrahydronaphthalen-2-yl]quinazolin-4-amine	

EX04-019C-US

Page 7 of 14

Table 3

#	Name	Structure
16	4-[(1S)-2,3-dihydro-1H-inden-1-ylmethyl]-2-pyridin-4-ylquinazoline	
18	(1S,2R)-1-[(2-pyridin-4-ylquinazolin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	
19	1,1-dimethylethyl 4-[(2-pyridin-4-ylquinazolin-4-yl)amino]piperidine-1-carboxylate	
24	3-[(2-pyridin-4-ylquinazolin-4-yl)amino]naphthalen-2-ol	
25	N-{4-[(1-methylethyl)oxy]phenyl}-2-pyridin-4-ylquinazolin-4-amine	

Table 3





#	Name	Structure
31	(1S,2R)-1-[(6-chloro-2-pyridin-4-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
33	(1S,2R)-1-[(2-pyridin-3-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
45	(1S,2R)-1-[(6-bromo-2-pyridin-4-yl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
46	(1S,2R)-1-[[6,7-bis(methoxy)-2-pyridin-4-yl]quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	



Table 3

#	Name	Structure
48	(1S,2R)-1-[[2-pyridin-4-yl-7-(trifluoromethyl)quinazolin-4-yl]amino]-2,3-dihydro-1H-inden-2-ol	
49	(1S,2R)-1-([2-[6-(methyloxy)pyridin-3-yl]quinazolin-4-yl]amino)-2,3-dihydro-1H-inden-2-ol	
51	(1S,2R)-1-[(7-methyl-2-pyridin-4-yl)quinazolin-4-yl]amino)-2,3-dihydro-1H-inden-2-ol	
54	(2S)-3-methyl-2-[(2-pyridin-4-yl)quinazolin-4-yl]amino]butan-1-ol	
55	(2S)-2-phenyl-2-[(2-pyridin-4-yl)quinazolin-4-yl]amino]ethanol	

Table 3

#	Name	Structure
56	(2R)-2-phenyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]ethanol	
57	(1S,2R)-1-[(2-pyridin-4-ylpyrimidin-4-yl)amino]-2,3-dihydro-1H-inden-2-ol	
61	(2S)-3-phenyl-2-[(2-pyridin-4-ylquinazolin-4-yl)amino]propan-1-ol	
62	2-[(phenylmethyl)(2-pyridin-4-ylquinazolin-4-yl)amino]ethanol	
63	(1S,2R)-1-{[2-(2-aminopyrimidin-4-yl)quinazolin-4-yl]amino}-2,3-dihydro-1H-inden-2-ol	

Table 3

#	Name	Structure
66	2-{4-[(2-pyridin-4-ylquinazolin-4-yl)amino]piperazin-1-yl}ethanol	 : and
67	N-piperidin-1-yl-2-pyridin-4-ylquinazolin-4-amine	

31. (previously presented) A pharmaceutical composition comprising the compound according to claim 9 and a pharmaceutically acceptable carrier.

32-38. (cancelled)